^
Association details:
| Biomarker: | IKZF1 deletion + IKZF3 deletion |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | avadomide (CC-122) (Cereblon modulator, Pleiotropic pathway modifier) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen
Published date:
04/13/2021
Excerpt:
To further characterize the role of IKZF1 and IKZF3 in mediating the response to CC-122 in DLBCL...Deletion of IKZF3 reduced cell proliferation by 50% to 75%...Compared with single knockout of IKZF1 or IKZF3, simultaneous elimination of both IKZF1 and IKZF3 produced synergistic inhibition of cell proliferation in SU-DHL-4, U-2932, and RIVA cells, and additive growth suppression in KARPAS-422, SU-DHL-16, and HT cells...These results suggest that IKZF1 and IKZF3 play a redundant role in maintaining cell survival and growth in DLBCL cell lines, and that loss of both IKZF1 and IKZF3 is sufficient to account for the antiproliferative effects of CC-122 in DLBCL cells.
DOI:
10.1182/bloodadvances.2020003431
